Drugs / Vosaroxin
Vosaroxin
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01913951 | Nov 2013 → Dec 2016 | myelodysplastic syndrome | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00246662 | Nov 2005 → Dec 2008 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00094159 | Oct 2004 → ? | neoplasm | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00091585 | Jun 2004 → Nov 2006 | neoplasm | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01980056 | Oct 2013 → Jan 2015 | myelodysplastic syndrome | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1/2 | NCT01893320 | Jul 2013 → Jan 2021 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00541866 | Oct 2007 → Feb 2012 | acute myeloid leukemia | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03338348 | Apr 2018 → Oct 2019 | acute myeloid leukemia, myelodysplastic syndrome with excess blasts-2 | University of Ulm | Completed | No outcome recorded |
| Phase 2 | NCT02658487 | Mar 2016 → Apr 2019 | acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome, myeloid sarcoma, therapy related acute myeloid leukemia and myelodysplastic syndrome | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00607997 | May 2008 → Nov 2009 | acute myeloid leukemia, myelodysplastic syndrome | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00408603 | Dec 2006 → Jun 2010 | malignant epithelial tumor of ovary | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00298896 | Feb 2006 → Aug 2007 | small cell lung carcinoma | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00252382 | Dec 2005 → Mar 2007 | non-small cell lung carcinoma | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT02416388 | Jan 2015 → Jul 2025 overdue | acute myeloid leukemia | University Hospital, Angers | Recruiting | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT01191801 | Dec 2010 → Sep 2014 | acute myeloid leukemia | Sunesis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02485353 | Oct 2015 → May 2016 | acute myeloid leukemia | Hamid Sayar | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02272478 Comparator | Oct 2014 → Feb 2021 | acute myeloid leukemia, myelodysplastic syndrome | Cardiff University | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vosaroxin | “Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II.” PMID 25381131 ↗ Nov 2014 |
| Known as | AG-7352 | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Known as | SNS-595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00252382 ↗ |
| Known as | SPC-595 | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Known as | Voreloxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00408603 ↗ |
| Known as | Vosaroxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Known as | Vosaroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Action | Inhibit | “inhibiting topoisomerase II” NCT00252382 ↗ |
| Modality | Small molecule | “a first in class anticancer quinolone derivative” NCT00252382 ↗ |
| Route | Intravenous | “SNS-595 given intravenously once every 3 weeks” NCT00091585 ↗ |